ストックスクリーナーアプリを入手
83.89
1.10%
-0.82
前日終値:
$84.71
開ける：
$84.16
24時間の取引高:
3.14M
Relative Volume:
0.23
時価総額：
$209.56B
収益：
$63.43B
当期純損益:
$16.42B
株価収益率:
12.93
EPS:
6.49
ネットキャッシュフロー:
$14.72B
1週間 パフォーマンス:
-0.40%
1か月 パフォーマンス:
+3.83%
6か月 パフォーマンス:
-11.48%
1年 パフォーマンス:
-28.90%
1日の値動き範囲:
$82.82
$84.32
1週間の範囲:
$82.82
$85.81
52週間の値動き範囲:
$73.31
$119.38
Merck Co Inc Stock (MRK) Company Profile
MRK を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
83.90 | 211.59B | 63.43B | 16.42B | 14.72B | 6.49 |
|
LLY
Lilly Eli Co
|
723.47 | 651.91B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
178.85 | 429.72B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
210.39 | 375.50B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
128.65 | 251.14B | 53.40B | 13.68B | 16.89B | 6.9231 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-14 | ダウングレード | Citigroup | Buy → Neutral |
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Neutral |
| 2025-02-18 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2025-02-10 | ダウングレード | TD Cowen | Buy → Hold |
| 2025-01-08 | ダウングレード | Truist | Buy → Hold |
| 2024-12-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-12-04 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-11-11 | ダウングレード | Daiwa Securities | Buy → Neutral |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-03-11 | ダウングレード | Societe Generale | Hold → Sell |
| 2024-01-04 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-11-09 | 開始されました | Deutsche Bank | Buy |
| 2023-10-27 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-10-20 | アップグレード | UBS | Neutral → Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Hold |
| 2023-04-13 | アップグレード | Citigroup | Neutral → Buy |
| 2023-03-28 | ダウングレード | Societe Generale | Buy → Hold |
| 2023-03-13 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-03-06 | 開始されました | Jefferies | Buy |
| 2023-02-22 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2023-01-04 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-10-10 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-09-14 | アップグレード | Berenberg | Hold → Buy |
| 2022-07-06 | アップグレード | Daiwa Securities | Neutral → Buy |
| 2022-06-06 | 再開されました | SVB Leerink | Outperform |
| 2022-04-06 | 再開されました | Morgan Stanley | Equal-Weight |
| 2021-12-17 | 開始されました | Goldman | Buy |
| 2021-12-16 | 開始されました | Daiwa Securities | Neutral |
| 2021-12-13 | ダウングレード | UBS | Buy → Neutral |
| 2021-12-09 | 開始されました | Wells Fargo | Overweight |
| 2021-12-07 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-11-29 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-11-19 | 開始されました | BMO Capital Markets | Market Perform |
| 2021-11-01 | アップグレード | Argus | Hold → Buy |
| 2021-09-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-05-20 | ダウングレード | Argus | Buy → Hold |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Sector Perform |
| 2020-11-10 | 再開されました | Bernstein | Outperform |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-08-03 | アップグレード | Goldman | Neutral → Buy |
| 2020-06-12 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2020-02-27 | 開始されました | Barclays | Overweight |
| 2020-01-07 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2019-10-17 | 再開されました | BofA/Merrill | Neutral |
| 2019-08-16 | 開始されました | SVB Leerink | Outperform |
| 2019-07-03 | 開始されました | Mizuho | Buy |
| 2019-05-28 | 開始されました | Goldman | Neutral |
| 2019-05-13 | アップグレード | Atlantic Equities | Neutral → Overweight |
| 2018-10-16 | 繰り返されました | Citigroup | Buy |
| 2018-10-09 | 再開されました | Guggenheim | Buy |
| 2018-04-23 | アップグレード | Goldman | Neutral → Buy |
| 2018-04-17 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2018-04-05 | アップグレード | Barclays | Equal Weight → Overweight |
| 2018-03-12 | アップグレード | Leerink Partners | Mkt Perform → Outperform |
| 2018-02-14 | 繰り返されました | Leerink Partners | Mkt Perform |
| 2018-02-07 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2018-01-16 | アップグレード | SunTrust | Hold → Buy |
すべてを表示
Merck Co Inc (MRK) 最新ニュース
Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences - Benzinga
Merck Says Phase 2 Study of Potential Lung Cancer Drug Showed 'Clinically Meaningful' Response Rates - MarketScreener
48% Response Rate: Breakthrough Cancer Drug Shows Promise in Advanced Lung Cancer Patients Trial - Stock Titan
Leerink Partners Maintained a Buy on Merck & Co (MRK) - uk.finance.yahoo.com
Goldman Sachs Slashes PT on Merck & Co. (MRK) to $94 From $99, Keeps a Buy Rating - MSN
Merck Shakes Off Some Claims From Cholesterol Drugs Suit - Law360
Merck (MRK) Impresses with New Cholesterol Drug in CORALreef Trial - MSN
Lilly-Merck Combo Drug For Lung Cancer Receives FDA Breakthrough StatusEli Lilly (NYSE:LLY) - Benzinga
2025 Wells Fargo Healthcare Conference - Merck.com
Biocytogen Enters into Agreement with Merck to Advance Antibody-Conjugated Lipid-Based Delivery Solutions - Yahoo Finance
Merck Taps US Investment-Grade Bond Market for Verona Purchase - Bloomberg.com
Merck's cholesterol drug gets a boost with another late-stage trial success - Reuters
This Merck Pill Promises Powerful Cholesterol Reduction Without Injections - Yahoo Finance
Merck's Portfolio and Solid Late-Stage Pipeline Defend Against Upcoming Keytruda Headwinds - Morningstar
Leerink Partners Remains Bullish on Merck & Co. (MRK) - MSN
No Spoils For VICTOR As Bayer/Merck & Co’s Verquvo Fails Phase III Trial - insights.citeline.com
Merck to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference - PharmiWeb.com
Merck & Co., Inc. Announces Positive Topline Results from the Phase 3 CORALreef Lipids Trial Evaluating the Safety and Efficacy of Enlicitide Decanoate - MarketScreener
Merck succeeds in late-stage trial for cholesterol drug - Seeking Alpha
Merck’s Investigational Oral PCSK9 Inhibitor Enlicitide Decanoate Met All Primary and Key Secondary Endpoints in Adults with Hypercholesterolemia in Pivotal CORALreef Lipids Study - Business Wire
Merck & Co., Inc. (MRK) Launches $3B Plan to Reinvest Ahead of Keytruda Patent Expiry in 2028 - Yahoo Finance
Merck & Co. Inc. (MRK) Initiates Phase 3 Trial on Breast Cancer Drug - MSN
Animal Health Market Trends, Key Player Strategies, and Growth Outlook to 2034 - GlobeNewswire Inc.
Co. Inc.Trade Ideas & Safe Swing Trade Setup Alerts - Newser
Merck & Co. (MRK) Announces First Patient Dosage in HERTHENA-Breast04 Phase 3 Trial - Yahoo Finance
Merck Provides New Results for VERQUVO® (vericiguat) in Patients with Chronic Heart Failure and Reduced Ejection Fraction - FinancialContent
Is Merck Stock Outperforming the Dow? - MSN
Merck (MRK) Up 2.8% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Merck to Participate in the 2025 Wells Fargo Healthcare Conference - PharmiWeb.com
Merck & Co., Inc. (MRK) Expands Targeted Therapy Pipeline with ADC Advances - Insider Monkey
Elfun Trusts Exits Merck & Co Inc, Impacting Portfolio by -1.85% in Q2 2025 - AInvest
Elfun Trusts Exits Merck & Co Inc, Impacting Portfolio by -1.85% - Yahoo Finance
Summit, Akeso Lung Cancer Drug Rivals Merck’s KeytrudaSummit Therapeutics (NASDAQ:SMMT) - Benzinga
Rising as One, Shining as Many - GlobeNewswire Inc.
Merck & Co., Inc. shares fall 1.73% intraday after Bernstein reiterates Neutral rating, lowering target price to EUR 138. - AInvest
Merck Demonstrates Ongoing Commitment to Advancing Cardiovascular Disease Management and Patient Care with New Data at the European Society of Cardiology Congress 2025 - The Globe and Mail
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Merck shares snapped six-session winning streak (NYSE:MRK) - Seeking Alpha
Merck & Co Inc (MRK) Highlights Gaps in Flea and Tick Prevention Adherence - AInvest
Skyhawk’s small-molecule RNA efforts draw Merck KGaA in $2B deal - BioWorld MedTech
Vets and Pet-Owners See Gaps in Flea and Tick Prevention, Highlighting Need for Year-Round Care, New Merck Animal Health Global Survey Finds - Business Wire
Can Keytruda Sustain Merck's Growth Through the Rest of 2025? - Yahoo Finance
Skyhawk Flies High With Another Big Pharma, Getting Up To $2bn In Merck KGaA Deal - insights.citeline.com
Translational medicine - Merck.com
Merck KGaA Signs $2 Billion Neurology Drug Pact With Skyhawk - Bloomberg.com
Merck: Shares Bucking The Gardasil Problem, Hiking My Price Target - Seeking Alpha
Q3 EPS Estimates for Merck & Co., Inc. Cut by Zacks Research - Defense World
Janux Therapeutics Receives $10M Milestone Payment from Merck for Advancing Cancer Therapy Collaboration - MSN
Merck & Co., Inc. (MRK) Announces Update on Phase 3 KEYNOTE-905 Trial - MSN
Merck Co Inc (MRK) 財務データ
収益
当期純利益
現金流量
EPS
1.25%
0.79%
大文字化:
|
ボリューム (24 時間):